EX-4.2





 Exhibit 4.2 
  

 
 ICOSAVAX, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

March 19, 2021 
  












 TABLE OF CONTENTS 

Page 
  

									
	1.	 	 Definitions
	  	 	1	 
			
	2.	 	 Registration Rights
	  	 	4	 
		 	 2.1
	  	 Demand Registration
	  	 	4	 
		 	 2.2
	  	 Company Registration
	  	 	6	 
		 	 2.3
	  	 Underwriting Requirements
	  	 	6	 
		 	 2.4
	  	 Obligations of the Company
	  	 	7	 
		 	 2.5
	  	 Furnish Information
	  	 	9	 
		 	 2.6
	  	 Expenses of Registration
	  	 	9	 
		 	 2.7
	  	 Delay of Registration
	  	 	9	 
		 	 2.8
	  	 Indemnification
	  	 	9	 
		 	 2.9
	  	 Reports Under Exchange Act
	  	 	11	 
		 	 2.10
	  	 Limitations on Subsequent Registration Rights
	  	 	11	 
		 	 2.11
	  	 “Market Stand-off” Agreement
	  	 	12	 
		 	 2.12
	  	 Restrictions on Transfer
	  	 	12	 
		 	 2.13
	  	 Termination of Registration Rights
	  	 	13	 
			
	3.	 	 Information and Observer Rights
	  	 	14	 
		 	 3.1
	  	 Delivery of Financial Statements
	  	 	14	 
		 	 3.2
	  	 Inspection
	  	 	15	 
		 	 3.3
	  	 Observer Rights
	  	 	15	 
		 	 3.4
	  	 Termination of Information, Inspection and Observer Rights
	  	 	16	 
		 	 3.5
	  	 Confidentiality
	  	 	16	 
			
	4.	 	 Rights to Future Stock Issuances
	  	 	17	 
		 	 4.1
	  	 Right of First Offer
	  	 	17	 
		 	 4.2
	  	 Termination
	  	 	18	 
			
	5.	 	 Additional Covenants
	  	 	18	 
		 	 5.1
	  	 Insurance
	  	 	18	 
		 	 5.2
	  	 Employee Agreements
	  	 	18	 
		 	 5.3
	  	 Employee Stock
	  	 	18	 
		 	 5.4
	  	 Qualified Small Business Stock
	  	 	19	 
		 	 5.5
	  	 Matters Requiring Investor Director Approval
	  	 	19	 
		 	 5.6
	  	 Board Matters
	  	 	20	 
		 	 5.7
	  	 Successor Indemnification
	  	 	21	 
		 	 5.8
	  	 Indemnification Matters
	  	 	21	 
		 	 5.9
	  	 Right to Conduct Activities
	  	 	21	 
		 	 5.10
	  	 Critical Technology Matters
	  	 	21	 
		 	 5.11
	  	 Tax Matters
	  	 	22	 
		 	 5.12
	  	 Termination of Covenants
	  	 	22	 
			
	6.	 	 Miscellaneous
	  	 	22	 
		 	 6.1
	  	 Successors and Assigns
	  	 	22	 
		 	 6.2
	  	 Governing Law
	  	 	 23
	 
		 	 6.3
	  	 Counterparts
	  	 	 23
	 
		 	 6.4
	  	 Titles and Subtitles
	  	 	 23
	 


  
 i 














									
		 	 6.5
	  	 Notices
	  	 	23	 
		 	 6.6
	  	 Amendments and Waivers
	  	 	23	 
		 	 6.7
	  	 Severability
	  	 	24	 
		 	 6.8
	  	 Aggregation of Stock
	  	 	24	 
		 	 6.9
	  	 Additional Investors
	  	 	24	 
		 	 6.10
	  	 Entire Agreement; Effect on Prior Agreement
	  	 	24	 
		 	 6.11
	  	 Dispute Resolution
	  	 	25	 
		 	 6.12
	  	 Waiver of Jury Trial
	  	 	25	 
		 	 6.13
	  	 Delays or Omissions
	  	 	25	 

 Schedule A    -        Schedule of Investors 

Schedule B    -        Schedule of Key Holders 

  
 ii 













 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of March 19,
2021, by and among Icosavax, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, (each of which is referred to in this Agreement as an “Investor”), each of the
stockholders listed on Schedule B hereto (each of whom is referred to herein as a “Key Holder”) and any additional purchaser of Preferred Stock (as defined below) that becomes a party to this Agreement in accordance with
Section 6.9 hereof. 
 RECITALS 

WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of the Company’s Series A-1 Preferred Stock (as defined below) and Series A-2 Preferred Stock (as defined below) and possess certain registration rights, information rights, rights of first offer and
other rights pursuant to that certain Investors’ Rights Agreement, dated as of August 15, 2019, by and among the Company and such Existing Investors (the “Prior Agreement”); 

WHEREAS, the Existing Investors are holders of a majority of the Registrable Securities (as defined in the Prior
Agreement) of the Company as of the date hereof, and desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement; and

 WHEREAS, certain of the Investors are parties to that certain Series B Preferred Stock Purchase Agreement of even
date herewith by and among the Company and such Investors (as may be amended from time to time, the “Purchase Agreement”), under which certain of the Company’s and such Investors’ obligations are conditioned upon the
execution and delivery of this Agreement by such Investors, the Key Holders and the Company. 
 NOW, THEREFORE, the
Company and the Existing Investors hereby agree that the Prior Agreement is hereby amended and restated in its entirety as set forth herein, and the parties to this Agreement further agree as follows: 

 

	 	1.	 Definitions. For purposes of this Agreement: 



“Adams Street” means Adams Street Growth Equity Fund VII or any of its Affiliates. 

“Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly,
controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer, director or trustee of such Person, or any venture capital fund, investment company or fund or any
other entity now or hereafter existing that is controlled by one or more general partners, managing members or investment adviser of, or shares the same management company or investment adviser with, such Person. 

“Aventis” means Aventis, Inc. or any of its Affiliates. 

“Board” means the Company’s Board of Directors. 

“Certificate of Incorporation” means the Company’s Amended and Restated Certificate of Incorporation, as
may be amended from time to time. 












 “Common Stock” means shares of the Company’s common
stock, par value $0.0001 per share. 
 “Competitor” means, as of any date, a Person engaged, directly or
indirectly (including through any partnership, limited liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in the business conducted or proposed to be conducted by the Company on
such date, but shall not include the Major Investors and their Affiliates, or any financial investment firm or collective investment vehicle that, together with its Affiliates, holds less than twenty percent (20%) of the outstanding equity of any
Competitor and does not, nor do any of its Affiliates, have a right to designate any members of the board of directors of any Competitor. 

“Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become
subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue
statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to
state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of
the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

“Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for
(in each case, directly or indirectly), Common Stock, including options and warrants. 
 “DPA” means
Section 721 of the Defense Production Act, as amended, including all implementing regulations thereof. 

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. 
 “Excluded Registration” means (i) a registration relating to the sale or
grant of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form
that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is
Common Stock issuable upon conversion of debt securities that are also being registered. 
 “Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

“Form S-3” means such form under the Securities Act as in
effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits forward incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

“GAAP” means generally accepted accounting principles in the United States as in effect from time to time.

 “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

  
 2 













 “Immediate Family Member” means a child, stepchild,
grandchild, parent, stepparent, grandparent, spouse, life partner or similar statutorily-recognized domestic partner, sibling, mother-in-law, father-in-law, son-in-law,
daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, of a natural person referred to herein. 

“Initiating Holders” means, collectively, Holders who properly initiate a registration request under this
Agreement. 
 “IPO” means the Company’s first underwritten public offering of its Common Stock under
the Securities Act. 
 “Key Holder Registrable Securities” means (i) the shares of Common Stock held
by the Key Holders, and (ii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in
replacement of such shares. 
 “Major Investor” means any Investor that, individually or together with such
Investor’s Affiliates, holds at least $4,999,990 of shares of Registrable Securities, based on the original purchase prices of such securities, and solely for purposes of Section 4 hereof, University of Washington
(“UW”). 
 “NanoDimension” means NanoDimension III, L.P. or any of its Affiliates. 

“New Securities” means, collectively, equity securities of the Company, whether or not currently authorized,
as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

“Person” means any individual, corporation, partnership, trust, limited liability company, association or
other entity. 
 “Preferred Directors” means, collectively, the Series
A-1 Directors and the Series B Director. 
 “Preferred Stock”
means, collectively, the Series A-1 Preferred Stock, the Series A-2 Preferred Stock, the Series B-1 Preferred Stock and the
Series B-2 Preferred Stock. 
 “Qiming” meas Qiming U.S. Healthcare
Fund II, L.P or any of its Affiliates. 
 “RA Capital” means RA Capital NEXUS Fund II, L.P. or any of its
Affiliates. 
 “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion
of the Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company acquired by the
Investors after the date hereof; (iii) the Key Holder Registrable Securities, provided, however, that such Key Holder Registrable Securities shall not be deemed Registrable Securities and the Key Holders shall not be deemed Holders for the
purposes of Sections 2.1 (and any other applicable Section or Subsection with respect to registrations under Subsection 2.1) and 2.10 and the first sentence of Section 6.6; and (iv) any Common
Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses
(i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not


  
 3 













 
assigned pursuant to Section 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to
Section 2.13 of this Agreement. 
 “Registrable Securities then
outstanding” means the number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then
exercisable and/or convertible securities that are Registrable Securities. 
 “Restricted Securities” means
the securities of the Company required to be notated with the legend set forth in Subsection 2.12(b) hereof. 

“SEC” means the Securities and Exchange Commission. 

“SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

“SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. 
 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer
taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Subsection 2.6.

 “Series A-1 Director” means any director of the
Company that the holders of record of the Series A-1 Preferred Stock are entitled to elect, exclusively and as a separate class, pursuant to the Company’s Certificate of Incorporation. 

“Series A-1 Preferred Stock” means the shares of Series A-1 Preferred Stock, $0.0001 par value per share, of the Company. 
 “Series A-2 Preferred Stock” means shares of Series A-2 Preferred Stock, $0.0001 par value per share, of the Company. 

“Series B Director” means any director of the Company that the holders of record of the Series B-1 Preferred Stock and Series B-2 Preferred Stock are entitled to elect, voting together as a single class on an as-converted basis,
pursuant to the Company’s Certificate of Incorporation. 
 “Series B-1
Preferred Stock” means shares of Series B-1 Preferred Stock, $0.0001 par value per share, of the Company. 

“Series B-2 Preferred Stock” means shares of Series B-2 Preferred Stock, $0.0001 par value per share, of the Company. 
  

	 	2.	 Registration Rights. The Company covenants and agrees as follows: 



2.1    Demand Registration. 

(a)    Form S-1 Demand. If at any time after the earlier
of (i) five (5) years after the date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration 

  
 4 













 
statement for the IPO, the Company receives a request from Holders holding at least fifty percent (50%) of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of $10 million or more, then the
Company shall (x) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event
within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the
Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty
(20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

(b)    Form S-3 Demand. If at any time when it is eligible
to use a Form S-3 registration statement, the Company receives a request from Holders of at least twenty percent (20%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $3 million, then the Company
shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the
date such request is given by the Initiating Holders file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any
other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

(c)    Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a
registration pursuant to this Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board it would be materially detrimental to the Company and its stockholders for
such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant
acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or
(iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or
effectiveness thereof shall be tolled correspondingly, for a period of not more than sixty (60) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than
once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such sixty (60) day period other than an Excluded
Registration. 
 (d)    The Company shall not be obligated to effect, or to take any action to effect,
any registration pursuant to Subsection 2.1(a) (i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty
(180) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective;
(ii) after the Company has effected two registrations pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Subsection 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b) (i)
during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration,


  
 5 













 
provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has
effected two registrations pursuant to Subsection 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Subsection
2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and
forfeit their right to one demand registration statement pursuant to Subsection 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d); provided
that if such withdrawal is during a period when the Company has deferred taking action pursuant to Subsection 2.1(c), then the Initiating Holders may withdraw their request for registration and such registration will not be counted as
“effected” for purposes of this Subsection 2.1(d). 
 2.2    Company
Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the public offering
of such securities solely for cash (other than in an Excluded Registration, a registration relating to a demand pursuant to Section 2.1 or the IPO), the Company shall, at such time, promptly give each Holder notice of such
registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Subsection 2.3, cause to be registered all of the Registrable
Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Subsection 2.2 before the effective date of such
registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Subsection
2.6. 
 2.3    Underwriting Requirements. 

(a)    If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the
Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The
underwriter(s) will be selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration
shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities
through such underwriting shall (together with the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of
this Subsection 2.3, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of
Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating
Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number
of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above
provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. 

(b)    In connection with any offering involving an underwriting of shares of the Company’s capital
stock pursuant to Subsection 2.2, the Company shall not be required to include any of 

  
 6 













 
the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in
such quantity, if any, as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by stockholders to be
included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to
include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine
that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as
practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance with the above
provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included
in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, (ii) the number of Registrable Securities included in the offering be reduced below thirty
(30%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s
securities are included in such offering, or (iii) notwithstanding (ii) above, any Registrable Securities which are not Key Holder Registrable Securities be excluded from such underwriting unless all Key Holder Registrable Securities are first
excluded from such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners,
retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be
deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling
Holder,” as defined in this sentence. 
 (c)    For purposes of Subsection 2.1, a
registration shall not be counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Subsection 2.3(a), the total number of Registrable Securities that Holders have requested to be included
in such registration statement are not actually included. 
 2.4    Obligations of the Company.
Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a)    prepare and file with the SEC a registration statement with respect to such Registrable Securities
and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective
for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day
period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in
the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty
(120) day period shall be extended for up to one hundred eighty (180) days to the extent necessary to keep the registration statement effective until all such Registrable Securities are sold; 

  
 7 













 (b)    prepare and file with the SEC such amendments
and supplements to such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such
registration statement; 
 (c)    furnish to the selling Holders such numbers of copies of a
prospectus, including a preliminary prospectus, as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d)    use its commercially reasonable efforts to register and qualify the securities covered by such
registration statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to
qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e)    in the event of any underwritten public offering, enter into and perform its obligations under an
underwriting agreement, in usual and customary form, with the underwriter(s) of such offering; 

(f)    use its commercially reasonable efforts to cause all such Registrable Securities covered by such
registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g)    provide a transfer agent and registrar for all Registrable Securities registered pursuant to this
Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h)    promptly make available for inspection by the selling Holders, any managing underwriter(s)
participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate
documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in
each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i)    notify each selling Holder, promptly after the Company receives notice thereof, of the time when
such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 

(j)    after such registration statement becomes effective, notify each selling Holder of any request by
the SEC that the Company amend or supplement such registration statement or prospectus. 
 In addition, the Company shall
ensure that, at all times after any registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may
implement a trading program under Rule 10b5-1 of the Exchange Act. 

  
 8 













 2.5    Furnish Information. It shall be a
condition precedent to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such
information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6    Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection
with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and
the reasonable fees and disbursements, not to exceed $50,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, that the Company shall not be required to pay
for any expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case
all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their
right to one registration pursuant to Subsections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the
condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay
any of such expenses and shall not forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this
Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

2.7    Delay of Registration. No Holder shall have any right to obtain or seek an injunction
restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8    Indemnification. If any Registrable Securities are included in a registration statement
under this Section 2: 
 (a)    To the extent permitted by law, the Company
will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for
each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or
other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however,
that the indemnity agreement contained in this Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not
be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any
such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration. 

(b)    To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and
hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the
Company, any underwriter (as defined in the 

  
 9 













 
Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to
the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such
registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages
may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such
settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution
under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c)    Promptly after receipt by an indemnified party under this Subsection 2.8 of notice
of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
Subsection 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other
indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may
be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a
reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure materially prejudices the indemnifying
party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Subsection 2.8. 

(d)    To provide for just and equitable contribution to joint liability under the Securities Act in any
case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court
of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for
indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will
contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the
indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the
indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to
information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however,
that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement,


  
 10 













 
and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty
of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to
Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e)    Notwithstanding the foregoing, to the extent that the provisions on indemnification and
contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f)    Unless otherwise superseded by an underwriting agreement entered into in connection with the
underwritten public offering, the obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and
otherwise shall survive the termination of this Agreement. 
 2.9    Reports Under Exchange Act.
With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a
registration on Form S-3, the Company shall: 
 (a)    make and
keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b)    use commercially reasonable efforts to file with the SEC in a timely manner all reports and other
documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c)    furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon
request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by
the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such
securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to
use such form). 
 2.10    Limitations on Subsequent Registration Rights. From and after the date
of this Agreement, the Company shall not, without the prior written consent of the Holders of at least thirty percent (30%) of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any
securities of the Company that would allow such holder or prospective holder (i) to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such
registration only to the extent that the inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included; or (ii) allow such holder or prospective holder to initiate a demand for
registration of any securities held by such holder or prospective holder; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with Subsection 6.9. 

  
 11 













 2.11    “Market Stand-off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus
relating to the IPO and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to
purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or
exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement for the IPO or (ii) enter into any swap or other arrangement that transfers to another, in whole or in
part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing
provisions of this Subsection 2.11 shall apply only to the IPO, shall not apply to transactions (including, without limitation, any swap, hedge or similar agreement or arrangement) or announcements, in each case, relating to securities
acquired in the IPO or securities acquired in open market or other transactions from and after the IPO or that otherwise do not involve or relate to securities of the Company owned by a Holder or its Affiliates prior to the IPO, shall not apply to
the sale of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the trustee of
the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers, directors
and stockholders (together with their Affiliates) owning more than 1% of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock) are subject to the same restrictions. The
underwriters in connection with such registration are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power and authority to enforce the provisions hereof as though
they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are necessary to
give further effect thereto. Any discretionary waiver or termination of the restrictions or any or all of such agreements by the Company or the underwriters shall apply pro rata to all Company stockholders that are subject to such agreements, based
on the number of shares subject to such agreements. 
 2.12    Restrictions on Transfer. 

(a)    The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise
transferred, and the Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are
intended to ensure compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and
hold such securities subject to the provisions and upon the conditions specified in this Agreement. Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or, following
the IPO, SEC Rule 144, in each case, to be bound by the terms of this Agreement. For the avoidance of doubt, a customary arrangement in connection with the deposit of Registrable Securities in a non-margin
custodial account shall not be deemed a sale, transfer or pledge for purposes of this Agreement so long as such registrable securities are in certificated form (it being understood that the Company may require the exchange of any such certificated
securities for book-entry shares upon the IPO). 
 (b)    Each certificate, instrument, or book entry
representing (i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization,
merger, 

  
 12 













 
consolidation, or similar event, shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND
THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making
a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

(c)    The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in
all respects with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the
proposed transaction or following the IPO, the transfer is made pursuant to SEC Rule 144, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer, provided that no such
notice shall be required if the intended sale, pledge or transfer complies with SEC Rule 144. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by
the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that
the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without
registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or
transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the
terms of the notice given by the Holder to the Company. The Company will not require such a notice, legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which
such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate, instrument, or
book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Subsection 2.12(b), except that
such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the
Securities Act. 
 2.13    Termination of Registration Rights. The right of any Holder to request
registration or inclusion of Registrable Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of: 

  
 13 













 (a)    the closing of a Deemed Liquidation Event, as
such term is defined in the Company’s Certificate of Incorporation; 
 (b)    such time after
consummation of the IPO as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s shares without limitation during a three-month period without registration; and 

(c)    the fifth (5th) anniversary of the IPO. 

 

	 	3.	 Information and Observer Rights. 



3.1    Delivery of Financial Statements. The Company shall deliver to each Major Investor,
provided that the Board has not reasonably determined that such Major Investor is a Competitor: 

(a)    as soon as practicable, but in any event within one hundred fifty (150) days after the end of
each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, (iii) a comparison between (x) the actual amounts as of and for such fiscal year and
(y) the comparable amounts for the prior year and as included in the Budget (as defined below) for such year, and (iv) a capitalization table as of the end of such year, with such financial statements referenced in (i) and (ii) to be
audited and certified by independent public accountants of at least regionally recognized standing selected by the Company; 

(b)    as soon as practicable, but in any event within forty-five
(45) days after the end of each quarter of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders’ equity as of the end of such
fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be
required in accordance with GAAP); 
 (c)    as soon as practicable, but in any event within forty-five
(45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for
shares of capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock, all in sufficient detail as to permit the Major Investors
to calculate their respective percentage equity ownership in the Company; 
 (d)    as soon as
practicable, but in any event thirty (30) days before the end of each fiscal year, a budget and business plan for the next fiscal year (collectively, the “Budget”), approved by the Board (including approval of at least three
(3) of the Preferred Directors) and prepared on a quarterly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the
Company; 
 (e)    with respect to the financial statements called for in Subsection 3.1(a) and
Subsection 3.1(b), an instrument executed by the chief financial officer and chief executive officer of the Company certifying that such financial statements were prepared in accordance with GAAP consistently applied with prior practice for
earlier periods (except as otherwise set forth in Subsection 3.1(b)) and fairly present the financial condition of the Company and its results of operation for the periods specified therein; and 

  
 14 













 (f)    such other information relating to the financial
condition, business, prospects, or corporate affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Subsection 3.1 to provide
information (i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company); or (ii) the disclosure
of which would adversely affect the attorney-client privilege between the Company and its counsel. 
 If, for any period,
the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial
statements of the Company and all such consolidated subsidiaries.
 Notwithstanding anything else in this Subsection
3.1 to the contrary, the Company may cease providing the information set forth in this Subsection 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a
registration statement (the “Cessation Period”) if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants
under this Subsection 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective and that, upon such reinstatement of the
Company’s covenants under this Section 3.1, the Company shall promptly deliver to each Major Investor all information required by this Section 3.1 for the Cessation Period. 

3.2    Inspection. The Company shall permit each Major Investor (provided that the Board has
not reasonably determined that such Major Investor is a Competitor), at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs,
finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Subsection
3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the
disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

3.3    Observer Rights. 

(a)    As long as Qiming owns not less than twenty-five percent (25%) of the shares of the Preferred
Stock it has purchased as of the date hereof (or an equivalent amount of Common Stock issued upon conversion thereof), subject to appropriate adjustment in the event of any stock dividend, stock split, combination, or other similar recapitalization
with respect to the Preferred Stock, the Company shall invite a representative of Qiming to attend all meetings of the Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes,
consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence all information so
provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if the Company reasonably determines, upon advice of counsel, that
access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest. 

(b)    As long as Aventis owns not less than twenty-five percent (25%) of the shares of the Preferred
Stock it has purchased as of the date hereof (or an equivalent amount of Common 

  
 15 













 
Stock issued upon conversion thereof), subject to appropriate adjustment in the event of any stock dividend, stock split, combination, or other similar recapitalization with respect to the
Preferred Stock, the Company shall invite a representative of Aventis to attend all meetings of the Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other
materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence all information so provided; and
provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if the Company reasonably determines, upon advice of counsel, that access to such
information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest. 

(c)    As long as RA Capital owns not less than twenty-five percent (25%) of the shares of the Series B-1 Preferred Stock it has purchased under the Purchase Agreement (or an equivalent amount of Common Stock issued upon conversion thereof), subject to appropriate adjustment in the event of any stock dividend, stock
split, combination, or other similar recapitalization with respect to the Series B-1 Preferred Stock, the Company shall invite a representative of RA Capital to attend all meetings of the Board in a nonvoting
observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors;
provided, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such
representative from any meeting or portion thereof if the Company reasonably determines, upon advice of counsel, that access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company
and its counsel or result in disclosure of trade secrets or a conflict of interest. 

3.4    Termination of Information, Inspection and Observer Rights. The
covenants set forth in Subsection 3.1, Subsection 3.2 and Subsection 3.3 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first
becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event
occurs first. 
 3.5    Confidentiality. Each Investor agrees that such Investor will keep
confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the
Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Subsection 3.5 by such Investor), (b) is
or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of
confidentiality such third party may have to the Company; provided, that an Investor may disclose confidential information (i) on a confidential basis, to its (or its Affiliates’) attorneys, accountants, consultants, and other
professionals to the extent necessary to obtain their services in connection with monitoring, and making decisions with respect to, its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such
Investor, if such prospective purchaser agrees to be bound by the provisions of this Subsection 3.5; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the
ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as requested by, or in such
Investor’s or its Affiliates’ ordinary course reporting to or examinations or similar processes by, any governmental authority, regulatory body or agency, stock exchange or self-regulatory organization


  
 16 













 
or (v) as may otherwise be required by law, regulation, rule, court order or subpoena (or other legal process), provided that, with respect to this clause (v), the Investor promptly
notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 
  

	 	4.	 Rights to Future Stock Issuances. 



4.1    Right of First Offer. 

(a)    Subject to the terms and conditions of this Section 4.1 and applicable
securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted to it in
such proportions as it deems appropriate, among (i) itself and (ii) its Affiliates; provided that each such Affiliate (x) is not a Competitor, unless such party’s purchase of New Securities is otherwise consented to
by the Board, and (y) agrees to enter into this Agreement and each of the Voting Agreement and Right of First Refusal and Co-Sale Agreement (as such terms are defined in the Purchase Agreement), as an
“Investor” under each such agreement (provided that any Competitor shall not be entitled to any rights as a Major Investor under Subsections 3.1, 3.2 and 4.1 hereof). 

(b)    The Company shall give notice (the “Offer Notice”) to each Major Investor,
stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. In addition, UW shall
notify Bill and Melinda Gates Foundation of the Offer Notice as required, if at all, by any agreement between UW and BMGF and the Company shall discuss in good faith with BMGF the potential participation by BMGF in the sale and purchase of such New
Securities in such amounts as may be mutually acceptable to the Company and BMGF. 
 (c)    By
notification to the Company within twenty (20) days after the Offer Notice is given, each Major Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New
Securities which equals the proportion that the Common Stock then held by such Major Investor (including all shares of Common Stock then issuable (directly or indirectly)) upon conversion and/or exercise, as applicable, of the Preferred Stock and
any other Derivative Securities then held by such Major Investor, bears to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities then
outstanding). At the expiration of such twenty (20) day period, the Company shall promptly notify each Major Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of
any other Major Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in
addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common
Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and
held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The
closing of any sale pursuant to this Subsection 4.1(c) shall occur within the later of ninety (90) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection
4.1(c). 
 (d)    If all New Securities referred to in the Offer Notice are not elected to be
purchased or acquired as provided in Subsection 4.1(c), the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1(c), offer and sell the remaining


  
 17 













 
unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the
Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived
and such New Securities shall not be offered unless first reoffered to the Major Investors in accordance with this Subsection 4.1. 

(e)    The right of first offer in this Subsection 4.1 shall not be applicable to
(i) Exempted Securities (as defined in the Company’s Certificate of Incorporation); (ii) shares of Series B-1 Preferred Stock and Series B-2 Preferred Stock
issued pursuant to the Purchase Agreement; and (iii) shares of Common Stock issued in the IPO. 

4.2    Termination. The covenants set forth in Subsection 4.1 shall terminate and be of no
further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed
Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation,. 
  

	 	5.	 Additional Covenants. 



5.1    Insurance. The Company shall maintain insurance policies, from financially sound and
reputable insurers, Directors and Officers liability insurance in an amount and on terms and conditions satisfactory to the Board, including approval of at least three (3) of the Preferred Directors, until such time as the Board, including
approval of at least three (3) of the Preferred Directors determines that such insurance should be discontinued. Notwithstanding any other provision of this Section 5.1 to the contrary, for so long as a Preferred
Director is serving on the Board, the Company shall not cease to maintain a Directors and Officers liability insurance policy in at least the amount of the initial policy approved by the Board unless approved by at least three (3) Preferred
Directors (for so long as at least three (3) Preferred Directors are then serving, and otherwise by a majority of the seated Preferred Directors). 

5.2    Employee Agreements. The Company will cause (i) each Person now or hereafter employed
by it or by any subsidiary or engaged by the Company or any subsidiary as a consultant or independent contractor with access to confidential information and/or trade secrets to enter into a non-disclosure and
proprietary information and inventions agreement; and (ii) each Person now or hereafter employed by it to enter into a non-competition (covering the period of employment) and non-solicitation agreement (covering a one-year period following employment termination). In addition, the Company shall not amend, modify, terminate, waive, or otherwise
alter, in whole or in part, any of the above-referenced agreements (or the form thereof to be used by the Company with employees after the date hereof) or any restricted stock agreement between the Company and any employee, without the consent of
the Board (or any committee thereof), including approval of at least three (3) of the Preferred Directors. Notwithstanding the foregoing, any approval by a duly elected committee of the Board shall only require the approval of at least two
(2) of the Preferred Directors. 
 5.3    Employee Stock. Unless otherwise approved
by the Board (or any committee thereof), including approval of at least three (3) of the Preferred Directors, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the
Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%)
of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months, and
(ii) a market stand-off provision substantially similar to that in Subsection 2.11. Without the 

  
 18 













 
prior approval by the Board (or any committee thereof), including approval of at least three (3) of the Preferred Directors, the Company shall not amend, modify, terminate, waive or
otherwise alter, in whole or in part, any stock purchase, stock restriction or option agreement with any employee or service provider if such amendment would cause it to be inconsistent with this Subsection 5.3. In addition, unless otherwise
approved by the Board (or any committee thereof), including approval of at least three (3) of the Preferred Directors, the Company shall retain (and not waive) a “right of first refusal” on employee transfers until the
Company’s IPO and shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock. Notwithstanding the foregoing, any approval by a duly elected committee of the Board shall only require
the approval of at least two (2) of the Preferred Directors. 
 5.4    Qualified Small Business
Stock.    The Company shall use commercially reasonable efforts to cause the shares of Series A-1 Preferred Stock and Series A-2 Preferred Stock,
as well as any shares into which such shares are converted, within the meaning of Section 1202(f) of the Internal Revenue Code (the “Code”), to constitute “qualified small business stock” as defined in
Section 1202(c) of the Code (collectively, the “Qualified Shares”); provided, however, that such requirement shall not be applicable if the Board determines, in its good-faith business judgment, that such qualification is
inconsistent with the best interests of the Company. The Company shall submit to its stockholders (including the Investors) and to the Internal Revenue Service any reports that may be required under Section 1202(d)(1)(C) of the Code and the
regulations promulgated thereunder. In addition, within twenty (20) business days after any Investor’s written request therefor, the Company shall, at its option, either (i) deliver to such Investor a written statement indicating
whether (and what portion of) such Investor’s Qualified Shares constitute “qualified small business stock” as defined in Section 1202(c) of the Code or (ii) deliver to such Investor such factual information in the
Company’s possession as is reasonably necessary to enable such Investor to determine whether (and what portion of) such Qualified Shares constitute “qualified small business stock” as defined in Section 1202(c) of the Code. 

5.5    Matters Requiring Investor Director Approval. So long as the holders of Preferred Stock are
entitled to elect at least one (1) or more Preferred Directors, the Company hereby covenants and agrees with each of the Investors that it shall not, nor shall it permit any Affiliate of the Company to, without approval of the Board (or any
committee thereof), which approval must include the affirmative vote of at least three (3) of the Preferred Directors, provided, that, any approval by a duly elected committee of the Board shall only require the approval of at least two
(2) of the Preferred Directors: 
 (a)    make, or permit any subsidiary to make, any loan or
advance to, or own any stock or other securities of, any subsidiary or other corporation, partnership, or other entity unless it is wholly owned by the Company; 

(b)    make, or permit any subsidiary to make, any loan or advance to any Person, including, without
limitation, any employee or director of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board; 

(c)    guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly,
any indebtedness, except for trade accounts of the Company or any subsidiary arising in the ordinary course of business; 

(d)    make any investment inconsistent with any investment policy approved by the Board; 

  
 19 













 (e)    incur any aggregate indebtedness or liability or
undertake any transaction or expenditure in excess of $500,000 that is not already included in a budget approved by the Board, other than trade credit incurred in the ordinary course of business; 

(f)    otherwise enter into or be a party to any transaction with any director, officer or employee of
the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person, including without limitation any “management bonus” or similar plan
providing payments to employees in connection with a Deemed Liquidation Event, except for transactions contemplated by this Agreement and the Purchase Agreement, except for expense reimbursement in the ordinary course of business and for other
transactions resulting in payments to or by the Company in an amount less than $10,000; 
 (g)    hire,
terminate, or change the compensation of the executive officers, including approving any option grants or stock awards to the executive officers; 

(h)    change the principal business of the Company, enter new lines of business, or exit the current
lines of business; 
 (i)    sell, assign, license, pledge or encumber material technology or
intellectual property, other than licenses granted in the ordinary course of business; 
 (j)    hire,
terminate or amend the terms of engagement of any financial advisors, investment bankers or underwriters (other than financial advisors assisting with cash management and similar treasury-related matters only); 

(k)    amend the accounting policies previously adopted or change the financial year of the Company; 

(l)    appoint or change the Company’s auditors; 

(m)    enter into an agreement with any senior level officer or any employee providing for total annual
compensation greater than or equal to $300,000; 
 (n)    acquire a substantial portion of the assets
or business of another company or entity (whether by merger, share purchase or asset acquisition) or any other acquisition of material assets; 

(o)    amend the Company’s 2017 Equity Incentive Plan or enter into a similar equity incentive plan;

 (p)    adopt or amend the Budget; or 

(q)    enter into any corporate strategic relationship involving the payment, contribution or assignment
by the Company or to the Company of money or assets greater than $500,000. 
 5.6    Board
Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the Board shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the nonemployee directors for all
reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board (or any committee
of the Board). 

  
 20 













 5.7    Successor Indemnification. If the Company
or any of its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so
that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board as in effect immediately before such transaction, whether such obligations are contained in the
Company’s Bylaws, its Certificate of Incorporation, or elsewhere, as the case may be. 

5.8    Indemnification Matters. The Company hereby acknowledges that one or more of the Preferred
Directors may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and certain of their Affiliates (collectively, the “Investor Indemnitors”). The Company
hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Preferred Director are primary and any obligation of the Investor Indemnitors to advance expenses or to provide indemnification for the same
expenses or liabilities incurred by such Preferred Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Preferred Director and shall be liable for the full amount of all expenses, judgments,
penalties, fines and amounts paid in settlement by or on behalf of any such Preferred Director to the extent legally permitted and as required by the Company’s Certificate of Incorporation or Bylaws of the Company (or any agreement between the
Company and such Preferred Director), without regard to any rights such Preferred Director may have against the Investor Indemnitors, and, (c) that it irrevocably waives, relinquishes and releases the Investor Indemnitors from any and all
claims against the Investor Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Investor Indemnitors on behalf of any such Preferred
Director with respect to any claim for which such Preferred Director has sought indemnification from the Company shall affect the foregoing and the Investor Indemnitors shall have a right of contribution and/or be subrogated to the extent of such
advancement or payment to all of the rights of recovery of such Preferred Director against the Company. The Preferred Directors and the Investor Indemnitors are intended third-party beneficiaries of this
Subsection 5.8 and shall have the right, power and authority to enforce the provisions of this Subsection 5.8 as though they were a party to this Agreement. 

5.9    Right to Conduct Activities. The Company hereby agrees and acknowledges that each
Major Investor is a professional investment organization, and as such reviews the business plans and related proprietary information of many enterprises, some of which may compete directly or indirectly with the Company’s business (as currently
conducted or as currently proposed to be conducted). The Company hereby agrees that, to the extent permitted under applicable law, each Major Investor shall not be liable to the Company for any claim arising out of, or based upon, (i) the
investment by a Major Investor in any entity competitive with the Company, or (ii) actions taken by any partner, officer, employee or other representative of such Major Investor to assist any such competitive company, whether or not such action
was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Investors
from liability associated with the unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary
duties to the Company. 
 5.10    Critical Technology Matters. If to the Company’s knowledge
(i) any pre-existing products or services provided by the Company are re-categorized by the U.S. government as a critical technology within the meaning of the DPA,
or would reasonably be considered to constitute the design, fabrication, development, testing, production or manufacture of a critical technology after a re-categorization of selected technologies by the U.S.
government, or (ii) after execution of the Purchase Agreement, the Company engages in any activity that could reasonably be considered to constitute the design, fabrication, development, testing, production or manufacture of a critical
technology within the 

  
 21 













 
meaning of the DPA: the Company shall promptly notify the Major Investors of (i) such change in the categorization of its products, services, or technology or (ii) its engagement in the
design, fabrication, development, testing, production or manufacture of a critical technology. 

5.11    Tax Matters. 

(a)    The Company and each Investor agrees that it is their intention that (a) the Series B-1 Preferred Stock shall be treated as stock that is not “preferred stock” within the meaning of Section 305 of the Internal Revenue Code of 1986, as amended (the “Code”) and the
Treasury Regulations issued thereunder, and (b) the Investors shall not be required to include in income as a dividend for U.S. federal income tax purposes any income or gain in respect of the Series B-1
Preferred Stock on account of the accrual of dividends thereon (including any deemed dividends or as a result of any discount) unless and until such dividends are declared and paid in cash. The Company and each Investor agrees agree to take no
positions or actions inconsistent with such treatment (including on any Internal Revenue Service Form 1099), unless otherwise required by a change in applicable law after the Closing, as defined in the Purchase Agreement. 

(b)    The Company shall use commercially reasonable efforts to cooperate with each Investor to structure
any redemption of the Series B-1 Preferred Stock permitted under the terms of the Company’s Certificate of Incorporation to be treated as a payment in exchange for stock pursuant to Section 302 of
the Code. 
 Promptly following (and in any event within ten (10) days after receipt of) written request by an
Investor, the Company shall provide such Investor with a written statement informing such Investor whether such Investor’s interest in the Company constitutes a United States real property interest. The Company’s determination shall comply
with the requirements of Treasury Regulation Section 1.897-2(h)(1) or any successor regulation, and the Company shall provide timely notice to the Internal Revenue Service, in accordance with and to the
extent required by Treasury Regulation Section 1.897-2(h)(2) or any successor regulation, that such statement has been made. The Company’s obligation to furnish such written statement shall continue
notwithstanding the fact that a class of the Company’s stock may be regularly traded on an established securities market or the fact that there is no Preferred Stock then outstanding. 

5.12    Termination of Covenants. The covenants set forth in this Section 5, except for
Subsections 5.8 and 5.9, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of
Section 12(g) or 15(d) of the Exchange Act or (iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation. 
  

	 	6.	 Miscellaneous. 



6.1    Successors and Assigns. The rights under this Agreement may be assigned (but only
with all related obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of
such Holder’s Immediate Family Members; or (iii) after such transfer, together with its Affiliates, is a Major Investor; provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished
with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound
by and subject to the terms and conditions of this Agreement, including the provisions of Subsection 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee
(1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the 

  
 22 













 
benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all
transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices,
or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is
intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

6.2    Governing Law. This Agreement shall be governed by the internal law of the State of
Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. 

6.3    Counterparts. This Agreement may be executed in two (2) or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of
2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.4    Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience
only and are not to be considered in construing or interpreting this Agreement. 

6.5    Notices. All notices and other communications given or made pursuant to this Agreement shall
be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail during the recipient’s normal business hours, and
if not sent during normal business hours, then on the recipient’s next business day; (iii) for addresses in the United States of America, five (5) days after having been sent by registered or certified mail, return receipt requested,
postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier (for addresses in the United States of America) or three (3) business days after deposit with an internationally
recognized overnight courier (for addresses outside the United States of America), in each case freight prepaid, specifying next business day (or, for addresses outside the United States of America, next available business day) delivery, with
written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on Schedule A or Schedule B hereto, or to the principal office of the Company and to the attention of the Chief
Executive Officer, in the case of the Company or to such email address or physical address as subsequently modified by written notice given in accordance with this Subsection 6.5. If notice is given to the Company, a copy shall also be sent
to Latham & Watkins LLP, 12670 High Bluff Drive, San Diego, CA 92130, Attn: Cheston J. Larson; and if notice is given to the Investors, a copy shall also be sent to DLA Piper LLP (US), 701 Fifth Avenue, Suite 6900, Seattle, WA 98104, Attn:
Steven R. Yentzer & Kerra J. Melvin and Wilmer Cutler Pickering Hale and Dorr LLP, 60 State Street, Boston, MA 02109, Attn: Jason Kropp. 

6.6    Amendments and Waivers. Any term of this Agreement may be amended or terminated and the
observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the Requisite Holders (as such term is defined in the
Company’s Certificate of Incorporation); provided that the Company may in its sole discretion waive compliance with Subsection 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed
assignment allegedly in violation of Subsection 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof may be 

  
 23 













 
waived by any waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the foregoing: 

(a)    this Agreement may not be amended or terminated and the observance of any term hereof may not be
waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or waiver (i) does not increase such Investor’s liabilities or obligations and (ii) applies to all Investors in the
same fashion; provided, that (x) a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its
terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction, (y) Subsections 3.1, 3.2 and 4, and any other section of this Agreement
applicable to the Major Investors (including this clause (y) of this Subsection 6.6) may not be amended, modified, terminated or waived without the written consent of the Requisite Holders, and (z) the definition of
“Competitor”, Subsections 3.3 and 5.9 and this clause (z) of this Subsection 6.6 may not be amended, modified, terminated or waived without the written consent of Qiming, Aventis, Adams Street, NanoDimension and
RA Capital. 
 (b)    Schedule A and Schedule B hereto may be amended by the Company from
time to time to add transferees of any Registrable Securities in compliance with the terms of this Agreement without the consent of the other parties; and Schedule A and Schedule B hereto may also be amended by the Company after the
date of this Agreement without the consent of the other parties to add information regarding any additional Investor who becomes a party to this Agreement in accordance with Subsection 6.9. The Company shall give prompt notice of any
amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Subsection 6.6 shall be
binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a
further or continuing waiver of any such term, condition, or provision. 
 6.7    Severability.
In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this
Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 

6.8    Aggregation of Stock. All shares of Registrable Securities, or of Preferred Stock, held or
acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate.

 6.9    Additional Investors. Notwithstanding anything to the contrary contained herein, if the
Company issues additional shares of Preferred Stock after the date hereof, any purchaser of such shares of Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement,
and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed
in writing to be bound by all of the obligations as an “Investor” hereunder. 

6.10    Entire Agreement; Effect on Prior Agreement. This Agreement (including any Schedules
and Exhibits hereto), the Certificate of Incorporation and the other Transaction Agreements (as defined in the Purchase Agreement) constitute the full and entire understanding and agreement among the parties with respect to the subject matter
hereof, and any other written or oral agreement relating to the 

  
 24 













 
subject matter hereof existing between the parties is expressly canceled. Upon the effectiveness of this Agreement, the Prior Agreement shall be deemed amended and restated and superseded and
replaced in its entirety by this Agreement and shall be of no further force or effect. 

6.11    Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to
the jurisdiction of the state courts of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement,
(b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of Delaware or the United States District Court for the District of Delaware, and (c) hereby
waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune
from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such
court. 
 6.12    Waiver of Jury Trial: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY
TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE
ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING
NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER
WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 

6.13    Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing
to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or
acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All
remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 
 [Remainder
of Page Intentionally Left Blank] 

  
 25 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	ICOSAVAX, INC.
		
	 By:
	 	 /s/ Adam K.
Simpson



 
			
	 Name:
	 	 Adam K. Simpson

	 Title:
	 	 President and Chief Executive Officer





			
		
	 Address:    
	 	 1616 Eastlake Ave. E

		 	 Suite 208

		 	 Seattle, WA 98102




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	QIMING U.S. HEALTHCARE FUND II, L.P.
	
	 By: Qiming U.S. Healthcare GP II, LLC,

its General Partner

		
	 By:
	 	 /s/ Mark McDade





			
	 Name:
	 	 Mark McDade

	 Title:
	 	 Managing Partner




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	JOE AND CLARA TSAI FOUNDATION LIMITED
	
	 By: Primary Management Limited,

	 As Sole Director

		
	 By:
	 	 /s/ Authorized Signatory




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	JEFFREY AND LIESL WILKE REVOCABLE TRUST
		
	 By:
	 	 /s/ Jeffrey A.
Wilke



 
			
	 Name:
	 	 Jeffrey A. Wilke

	 Title:
	 	 Trustee




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Siddharth B. Shenai

	 Siddharth B. Shenai




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Ingrid Pultz

	 Ingrid Pultz

	
	 /s/ Scott Pultz

	 Scott Pultz




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	PAGSGROUP, LLC
		
	 By:
	 	 /s/ Judy Pagliuca





			
	 Name:
	 	 Judy Pagliuca

	 Title:
	 	 Manager




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Brian Hongdi Gu

	 Brian Hongdi Gu




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	PNC INVESTMENTS, LLC
		
	 By:
	 	 /s/ Paul Clark





			
	 Name:
	 	 Paul Clark

	 Title:
	 	 Manager




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Colin Walsh

	 Colin Walsh




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Lansing Stewart

	 Lansing Stewart




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	STANLEY R. HOLTZMAN
		
	 By:
	 	 /s/ Douglas A.
Holtzman



 
			
	 Name:
	 	 Douglas A. Holtzman

	 Title:
	 	 Representative




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Cheston J. Larson

	 Cheston J. Larson




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	JBA INVESTORS, LLC
		
	 By:
	 	 /s/ Jeremy
Anderson



 
			
	 Name:
	 	 Jeremy Anderson

	 Title:
	 	 Manager




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	SAHSEN VENTURES, LLC
		
	 By:
	 	 /s/ Bryan White





			
	 Name:
	 	 Bryan White

	 Title:
	 	 Managing Member




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	ADAMS STREET 2016 DIRECT VENTURE/GROWTH FUND LP
	
	By: ASP 2016 Direct Management LP its General Partner
	By: ASP 2016 Direct Management LLC its General Partner
	By: Adams Street Partners, LLC its Managing Member


 
			
		
	 By:
	 	 /s/ Elisha P. Gould
III



 
			
	 Name:
	 	 Elisha P. Gould III

	 Title:
	 	 Partner



 
			
	
	ADAMS STREET 2017 DIRECT VENTURE/GROWTH FUND LP
	
	By: ASP 2017 Direct Management LP its General Partner
	By: ASP 2017 Direct Management LLC its General Partner
	By: Adams Street Partners, LLC its Managing Member


 
			
		
	 By:
	 	 /s/ Elisha P. Gould
III



 
			
	 Name:
	 	 Elisha P. Gould III

	 Title:
	 	 Partner



 
			
	
	ADAMS STREET 2018 DIRECT VENTURE/GROWTH FUND LP
	
	By: ASP 2018 Direct Management LP its General Partner
	By: ASP 2018 Direct Management LLC its General Partner
	By: Adams Street Partners, LLC its Managing Member


 
			
		
	 By:
	 	 /s/ Elisha P. Gould
III



 
			
	 Name:
	 	 Elisha P. Gould III

	 Title:
	 	 Partner




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	ADAMS STREET 2019 DIRECT GROWTH EQUITY FUND LP
	
	By: ASP 2019 Direct Management LP its General Partner
	By: ASP 2019 Direct Management LLC its General Partner
	By: Adams Street Partners, LLC its Managing Member


 
			
		
	 By:
	 	 /s/ Elisha P. Gould
III



 
			
	 Name:
	 	 Elisha P. Gould III

	 Title:
	 	 Partner



 
			
	
	ADAMS STREET VENTURE/GROWTH FUND VI LP
	
	By: ASP VG Management VI LP its General Partner
	By: ASP VG Management VI LLC its General Partner
	By: Adams Street Partners, LLC its Managing Member


 
			
		
	 By:
	 	 /s/ Elisha P. Gould
III



 
			
	 Name:
	 	 Elisha P. Gould III

	 Title:
	 	 Partner



 
			
	
	ADAMS STREET GROWTH EQUITY FUND VII LP
	
	By: ASP VG Management VII LP, its General Partner
	By: ASP VG Management VII LLC, its General Partner
	By: Adams Street Partners, LLC, its Managing Member


 
			
		
	 By:
	 	 /s/ Elisha P. Gould
III



 
			
	 Name:
	 	 Elisha P. Gould III

	 Title:
	 	 Partner




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	NANODIMENSION III, L.P.
	
	 By: NanoDimension III Management Limited, its General Partner

		
	 By:
	 	 /s/ Jonathan
Nicholson



 
			
	 Name:
	 	 Jonathan Nicholson

	 Title:
	 	 Director




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	AVENTIS, INC.
		
	 By:
	 	 /s/ Jason Hafler





			
	 Name:
	 	 Jason P. Hafler

	 Title:
	 	 Managing Director, Sanofi Ventures




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	RA CAPITAL HEALTHCARE FUND, L.P.
	
	 By: RA Capital Healthcare Fund GP, LLC

	 Its: General Partner

		
	 By:
	 	 /s/ Peter
Kolchinsky



 
			
	 Name:
	 	 Peter Kolchinsky

	 Title:
	 	 Manager




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	RA CAPITAL NEXUS FUND II, L.P.
	
	 By: RA Capital Nexus Fund II GP, LLC

	 Its: General Partner

		
	 By:
	 	 /s/ Peter
Kolchinksy



 
			
	 Name:
	 	 Peter Kolchinsky

	 Title:
	 	 Manager




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	GOOD VENTURES FOUNDATION LLC
		
	 By:
	 	 /s/ Rakesh Mehta





			
	 Name:
	 	 Rakesh Mehta

	 Title:
	 	 Authorized Signatory




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
	
	 By: Perceptive Advisors, LLC

		
	 By:
	 	 /s/ James H.
Mannix



 
			
	 Name:
	 	 James H. Mannix

	 Title:
	 	 Chief Operating Officer




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	JANUS HENDERSON GLOBAL LIFE SCIENCES FUND
	
	 By: Janus Capital Management LLC, its investment advisor

		
	 By:
	 	 /s/ Andrew Acker





			
	 Name:
	 	 Andrew Acker

	 Title:
	 	 Authorized Signatory




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	JANUS HENDERSON BIOTECH INNOVATION MASTER FUND LIMITED
	
	 By: Janus Capital Management LLC, its investment advisor

		
	 By:
	 	 /s/ Andrew Acker





			
	 Name:
	 	 Andrew Acker

	 Title:
	 	 Authorized Signatory




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	JANUS HENDERSON CAPITAL FUNDS PLC ON BEHALF OF ITS SERIES JANUS HENDERSON GLOBAL LIFE SCIENCES FUND
	
	 By: Janus Capital Management LLC, its investment advisor

		
	 By:
	 	 /s/ Andrew Acker





			
	 Name:
	 	 Andrew Acker

	 Title:
	 	 Authorized Signatory




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	JANUS HENDERSON HORIZON FUND - BIOTECHNOLOGY FUND
	
	 By: Janus Capital Management LLC, its investment advisor

		
	 By:
	 	 /s/ Andrew Acker





			
	 Name:
	 	 Andrew Acker

	 Title:
	 	 Authorized Signatory




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP
	
	By: Viking Global Opportunities Portfolio GP, LLC, its General Partner
		
	 By:
	 	 /s/ Katerina Novak





			
	 Name:
	 	 Katerina Novak

	 Title:
	 	 Authorized Signatory




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	CORMORANT PRIVATE HEALTHCARE FUND III, LP
	
	 By: Cormorant Private Healthcare GP, LLC

		
	 By:
	 	 /s/ Bihua Chen





			
	 Name:
	 	 Bihua Chen

	 Title:
	 	 Managing Member




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP
	
	 By: Cormorant Global Healthcare GP, LLC

		
	 By:
	 	 /s/ Bihua Chen





			
	 Name:
	 	 Bihua Chen

	 Title:
	 	 Managing Member




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	CRMA SPV, LP
	
	 By: Cormorant Asset Management, LP, its
attorney-in-fact

		
	 By:
	 	 /s/ Bihua Chen





			
	 Name:
	 	 Bihua Chen

	 Title:
	 	 Managing Member




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	OMEGA FUND VI, L.P.
	
	 By: Omega Fund VI GP, L.P., its General Partner

	
	 By: Omega Fund VI GP Manager, Ltd., its General Partner

		
	 By:
	 	 /s/ Otello
Stampacchia



 
			
	 Name:
	 	 Otello Stampacchia

	 Title:
	 	 Director




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	CITADEL MULTI-STRATEGY EQUITIES MASTER FUND LTD
	
	 By: Citadel Advisors LLC, its portfolio manager

		
	 By:
	 	 /s/ Shellane
Mulcahy



 
			
	 Name:
	 	 Shellane Mulcahy

	 Title:
	 	 Authorized Signatory




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

	
	KEY HOLDER:
	
	 /s/ Neil P. King

	 Neil P. King, Ph.D.




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	KEY HOLDER:
	
	LESLIE D. YAMADA 2016 TRUST
		
	 By:
	 	 /s/ Tadataka
Yamada



 
			
	 Name:
	 	 Tadataka (Tachi) Yamada

	 Title: Trustee




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	KEY HOLDER:
	
	THE ADAM K. AND MARIA M. SIMPSON FAMILY TRUST DTD. 04/27/07
		
	 By:
	 	 /s/ Adam K.
Simpson



 
			
	 Name:
	 	 Adam K. Simpson

	 Title: Trustee




  

[SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT] 













 SCHEDULE A 

INVESTORS 
  

	
	 Name 

	
	 Sahsen Ventures, LLC

	
	 Joe and Clara Tsai Foundation Limited

	
	 Jeffrey and Liesl Wilke Revocable Trust

	
	 Siddharth B. Shenai

	
	 Scott and Ingrid Pultz

	
	 PagsGroup, LLC

	
	 Brian Hongdi Gu

	
	 PNC Investments, LLC

	
	 Stanley R. Holtzman

	
	 Cheston J. Larson

	
	 JBA Investors, LLC

	
	 Qiming U.S. Healthcare Fund II, L.P.

	
	 Adams Street Growth Equity Fund VII LP

	
	 Adams Street Venture/Growth Fund VI LP

	
	 Adams Street 2019 Direct Growth Equity Fund LP

	
	 Adams Street 2018 Direct Venture/Growth Fund LP

	
	 Adams Street 2017 Direct Venture/Growth Fund LP

	
	 Adams Street 2016 Direct Venture/Growth Fund LP

	
	 NanoDimension III, L.P.

	
	 Aventis, Inc.

	
	 Lansing Stewart

	
	 Colin Walsh

	
	 Good Ventures Foundation LLC

	
	 RA Capital Healthcare Fund, L.P.

	
	 RA Capital NEXUS Fund II, L.P.

	
	 JANUS HENDERSON GLOBAL LIFE

SCIENCES FUND

	
	 JANUS HENDERSON BIOTECH

INNOVATION MASTER FUND

LIMITED

	
	 JANUS HENDERSON CAPITAL FUNDS

PLC ON BEHALF OF ITS SERIES

JANUS HENDERSON GLOBAL LIFE

SCIENCES FUND

	
	 JANUS HENDERSON HORIZON FUND

- BIOTECHNOLOGY FUND

	
	 VIKING GLOBAL OPPORTUNITIES

ILLIQUID INVESTMENTS

SUB-MASTER LP

	
	 Perceptive Life Sciences Master Fund, Ltd.

	
	 Cormorant Private Healthcare Fund III, LP

	
	 Cormorant Global Healthcare Master Fund, LP

	
	 CRMA SPV, LP















	
	
	 OMEGA FUND VI, L.P.

	
	 Citadel Multi-Strategy Equities Master

Fund Ltd.

	
	 Neil P. King, Ph.D.

	
	 Leslie D. Yamada 2016 Trust

	
	 The Adam K. and Maria M. Simpson Family Trust dtd. 04/27/07